Trulicity Lawsuit: Where the Stomach and Vision-Loss Cases Stand in October 2026
Questions about this case?
AI Legal Assistant · free · answers in seconds · general information, not legal advice
The Trulicity lawsuit is really two federal MDLs in Philadelphia. Patients allege Eli Lilly’s weekly diabetes injection (dulaglutide) caused stomach paralysis, bowel blockage or sudden vision loss, and they sue alongside Ozempic, Wegovy and Mounjaro users. Why it is in the news: a five-day expert hearing was scheduled for September 14–18, 2026, and no ruling is posted. A separate Trulicity rebate-fraud case that Lilly itself filed in Miami is about money, not patients. There is no Trulicity settlement and no claim form.
Editorially Reviewed — Content reviewed for accuracy using published legal research, government data, and verified court records. See our methodology
Reviewed by Leonard Goldberg, Editor · Last updated
What the Trulicity Lawsuits Allege
Lilly’s quarterly report says that since August 2023 plaintiffs have sued Lilly and Novo Nordisk over injuries they allege followed use of incretin medicines, “including Mounjaro, Trulicity, and Zepbound.”
Stomach and bowel injuries. The lawsuits allege that GLP-1 drugs such as Trulicity can cause gastroparesis (stomach paralysis) and other gastrointestinal injuries. The court frames the shared questions as whether the makers “knew or should have known” of that risk, whether they adequately warned patients or their doctors, and whether their safety statements were misleading.
Vision loss. A second group of cases alleges NAION, sudden damage to the optic nerve that can cause lasting vision loss. The court’s page for that MDL names Trulicity as the Lilly drug involved.
These are individual injury lawsuits, not a consumer class action. Lilly and Novo Nordisk deny the allegations.
Case Details
Stomach and bowel injuries: In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094, No. 2:24-md-03094, U.S. District Court for the Eastern District of Pennsylvania, Judge Karen S. Marston. Court page: paed.uscourts.gov.
Vision loss (NAION): MDL No. 3163, same court, same judge. Court page: paed.uscourts.gov.
Outside federal court: Lilly reports similar cases in Delaware, Indiana and New Jersey state courts, plus two class action petitions in Israel and two in Canada.
Not a patient case: in May 2026 Lilly itself sued a Florida mail-order pharmacy, DrugPlace, and related organizations and individuals in federal court in Miami. Lilly alleges they claimed more than $200 million in Trulicity rebates for patients who, Lilly says, did not exist or could not be verified, while reselling the drug. In June 2026, U.S. District Judge Federico Moreno barred the defendants from submitting more rebate claims to Lilly or destroying records. The defendants have not been found liable, and patients have no claim in that case.
Status on October 5, 2026: Waiting for the Expert Ruling
The Judicial Panel on Multidistrict Litigation’s report of October 1, 2026 lists 4,025 pending cases in MDL 3094 (4,139 filed in total) and 247 in the vision-loss MDL 3163. Those totals cover every GLP-1 drug in the litigation; the court publishes no Trulicity-only count.
The key event is the Rule 702 (“Daubert”) hearing Judge Marston scheduled for September 14–18, 2026, on cross-cutting issues 2 and 3 in MDL 3094. An order dated August 28, 2026 had moved it from September 10–18. The question is whether the plaintiffs’ expert evidence is reliable enough to reach a jury. As of October 5, 2026, the court’s list of MDL 3094 orders shows no ruling from that hearing. Whatever the judge decides will shape which Trulicity claims go forward.
Follow this case
There's no claim deadline yet. We'll email you if a settlement opens a claim period.
Who Could Have a Claim
There is nothing to sign up for. MDL 3094 and MDL 3163 collect individual lawsuits. Nobody is included automatically; each person files their own case, usually through a lawyer.
The cases generally involve people who took Trulicity (or another GLP-1 drug) and were diagnosed with a serious stomach or bowel injury such as gastroparesis or bowel obstruction, or with NAION in one eye. Medical records decide these cases: the diagnosis, the tests behind it, and when the injury started compared with when the drug was started.
Injury lawsuits have filing deadlines (statutes of limitations) that vary by state and often run from the diagnosis. A lawyer can tell you which one applies. How firms sort injury tiers: our GLP-1 lawsuit calculator.
Is There a Trulicity Settlement?
Dollar ranges on law-firm websites are projections, not court figures. If these cases ever resolve, injury claims are usually valued one by one or through a grid that weighs diagnosis, treatment (hospital stay, surgery, feeding tube) and lasting harm, not split evenly.
The Miami rebate case pays patients nothing: Lilly is the plaintiff, seeking its own money back. For settlements paying now, see our open class action settlements list; to see how class payouts are usually divided, try the class action payout calculator.
How cases like this one end
Our copy of the federal courts’ own case database covers 166,050 health care/pharmaceutical product liability casesclosed in U.S. federal district courts between 2015 and 2025:
- 34.5% ended in a settlement recorded by the court. Another 17.9% were dismissed voluntarily, which often follows a private settlement — so the real settlement share sits between 34.5% and 52.4%.
- 9% were decided on a motion before any trial.
- 1 in 2,863 reached a trial (0%), after a median of 32 months.
- Median time from filing to the end of the case: 26.3 months.
- Almost none record a money award in this data (18 of 166,050), and the recorded figures are capped, so we do not publish an average.
These are base rates for this type of case (federal pharmaceutical product liability cases) — not a prediction about this lawsuit, and not legal advice. Source: Federal Judicial Center, Integrated Database (civil), analysed by Settlement Insight. Cases heard in state courts are not included.
Trulicity Lawsuit Timeline
- 1
August 2023 — First Suits Naming Lilly
Patients begin suing Eli Lilly and Novo Nordisk over injuries they allege followed use of Trulicity, Mounjaro and other incretin drugs, according to Lilly’s filings.
- 2
February 2024 — MDL 3094 Gets Under Way
Federal stomach-injury cases are centralized in Philadelphia before Judge Karen S. Marston. Her first case management order is dated February 15, 2024.
- 3
Vision-Loss Cases Get Their Own MDL
NAION claims are handled in a separate MDL 3163, same court and judge. The court’s page for it lists Trulicity among the drugs.
- 4
May 2026 — Lilly Sues Over Trulicity Rebates
In Miami federal court, Lilly alleges a pharmacy scheme claimed more than $200 million in rebates for Trulicity patients who, Lilly says, did not exist or could not be verified. In June 2026 Judge Federico Moreno bars new rebate claims. No patient payout is involved.
- 5
September 14–18, 2026 — Expert Hearing
Five-day Rule 702 hearing on cross-cutting issues 2 and 3 in MDL 3094, moved from September 10–18 by an August 28, 2026 order.
- 6
October 2026 — Ruling Pending, No Settlement
The JPML lists 4,025 pending cases in MDL 3094 and 247 in MDL 3163 on October 1, 2026. As of October 5, 2026, no expert ruling is posted and no settlement exists.
Three Things to Watch For
Trulicity headlines now mix injury lawsuits and a rebate-fraud case, and that confusion is easy to exploit:
“Claim your Trulicity settlement” ads
There is no settlement and no official claims site. A form asking for your prescription history, insurance ID or Social Security number to “secure your payout” is collecting leads or data, not filing anything with a court.
“Your share of the $200 million”
The $200 million figure is what Lilly says it lost in rebates. Lilly is the one suing for it. No patient, church member or pharmacy customer is owed money from that case, and nobody legitimate will ask you for a fee to “release” it.
“Join the Trulicity class action”
The U.S. injury cases are individual lawsuits in an MDL, not a class you join. Signing up means hiring a law firm, so read the retainer and the fee percentage before you sign. Never pay an upfront fee to “register.”
Trulicity Lawsuit — Questions People Ask
Is there a Trulicity lawsuit settlement?
No. As of October 5, 2026, there is no Trulicity settlement, fund or claim form. The injury cases are in pretrial proceedings in MDL 3094 and MDL 3163 in Philadelphia, and Lilly’s filings disclose no settlement.
How many Trulicity lawsuits are there?
The court does not count Trulicity separately. On October 1, 2026, the JPML listed 4,025 pending cases in the GLP-1 stomach-injury MDL 3094 and 247 in the vision-loss MDL 3163, across all the drugs involved.
Is Trulicity part of the Ozempic lawsuit?
Yes. Trulicity and Mounjaro (Lilly) sit in the same federal MDL as Ozempic, Wegovy and Rybelsus (Novo Nordisk). Status across all brands: our GLP-1 lawsuit tracker and the Mounjaro lawsuit page.
What is the Trulicity rebate fraud lawsuit?
A separate case Lilly filed in May 2026 in federal court in Miami. Lilly alleges a mail-order pharmacy and related groups bought Trulicity, resold it, and still claimed more than $200 million in rebates for patients who did not exist or could not be verified. The church linked to the program is not a defendant and said it had no knowledge of the alleged fraud. It is not a patient case and pays patients nothing.
Can I sue over Trulicity and vision loss?
NAION claims are handled in MDL 3163, where the court’s page lists Trulicity. Those cases are at an early stage. More: our GLP-1 vision-loss lawsuit page.
Is there a Trulicity class action I can join?
Not in the U.S. The American cases are individual injury lawsuits. Lilly reports two class action petitions in Israel and two in Canada. Other cases against Lilly, including insulin pricing, are on our Eli Lilly lawsuit page.
Do I have to stop taking Trulicity to file a claim?
No lawsuit requires that, and the litigation is not medical advice. Do not stop or change a prescription without talking to your doctor.
When will the Trulicity lawsuit settle?
Nobody knows. The expert ruling from the September 2026 hearing is pending, no bellwether trial date appears on the court’s orders list, and the vision-loss track is still early. Anyone quoting a payout date is guessing.
Separate from this case: were you injured in the last 2 years?
Class-action payouts are fixed amounts through an administrator. A personal injury claim is a different case — and often worth far more. Free estimate, no obligation.
Related Consumer Brand Lawsuits
Mounjaro Lawsuit
Lilly's other GLP-1 drug in the same two federal MDLs
GLP-1 Lawsuit Tracker
Ozempic, Wegovy, Mounjaro and Trulicity cases in one overview
GLP-1 Vision Loss (NAION)
The separate MDL 3163 over sudden optic-nerve vision loss
Open Class Action Settlements
Settlements that are actually taking claims right now